hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 08:39:08 - browse：4875

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Steward Health Care Massachusetts hospitals face fiscal disaster

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

UCLA team creates talking throat patch for voice disorders

Steward Health Care Massachusetts hospitals face fiscal disaster

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

White House drug shortages task force keeps mum with Congress

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

hotspot

hotspot

focus

Supreme Court strikes down use of affirmative action

The history of OxyContin, told through Purdue Pharma documents

United colonoscopy coverage change 'may cost lives,' doctors say

RaDonda Vaught links Vanderbilt hospital issues to patient death

New air purifier tech could be key to improving indoor air quality

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

The high cost of giving birth even with insurance

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Moonlake's readout produced a cash windfall. Risks remain

How to save health care price transparency rules

knowledge

How to save health care price transparency rules

Male and female sex labels in research insufficient, scientists say

How to save health care price transparency rules

HHS secretary Becerra pressed on Change HealthCare cyberattack

RaDonda Vaught links Vanderbilt hospital issues to patient death

Timeline: Special counsel's investigation into Trump's handling of classified documents

hotspot

knowledge

explore

focus